8-K: Quoin Pharmaceuticals Settles CFO Departure Terms

Quoin Pharmaceuticals Ltd. finalized a separation agreement with former Chief Financial Officer Gordon Dunn, including a $433,620 severance and a $108,405 bonus.

Summary

• Quoin Pharmaceuticals Ltd. (the Company) entered into a Settlement Agreement with its former Chief Financial Officer, Gordon Dunn, effective August 15, 2025.
• Mr. Dunn's employment with the Company terminated on August 15, 2025.
• The agreement provides for a payment of $433,620 in equal bi-weekly installments, in lieu of 12 months' notice.
• Mr. Dunn will receive a bonus of $108,405 for the 2024 financial year, payable as a lump sum on the one-year anniversary of the Termination Date.
• The exercise period for Mr. Dunn's vested but unexercised non-qualified stock options has been extended from 90 days to 1 year and 9 months post-termination.
• The agreement includes a release of claims provision, settling all potential claims by Mr. Dunn against the Company.
• The Company will procure Directors and Officers (D&O) insurance coverage for Mr. Dunn for 6 years from the Termination Date.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are significant financial outlays for severance and a bonus, the agreement resolves potential claims and ensures cooperation from the former CFO, which is a positive for corporate stability. The costs are quantifiable and expected for such a separation.

Positives

• The agreement constitutes a full and final settlement of all potential claims by Mr. Dunn against the Company, its Group Companies, and their officers, employees, and workers.
• Mr. Dunn has waived any claim for compensation for loss of office.
• Mr. Dunn is bound by confidentiality and post-termination restrictions from his original Service Agreement.
• Mr. Dunn agrees to make himself reasonably available to cooperate with the Company in any internal investigation or legal proceedings.
• The Company represents it is not aware of any claims against Mr. Dunn.

Negatives

• A significant payment of $433,620 is being made in lieu of notice.
• A bonus of $108,405 for the 2024 financial year is being paid, despite Mr. Dunn having no prior entitlement to it.
• The Company is incurring costs related to the separation, including the severance, bonus, and extended D&O insurance.

Risks

• Potential for Mr. Dunn to breach material provisions of the agreement (e.g., confidentiality, non-disparagement, post-termination restrictions), which would lead to indemnification obligations for Mr. Dunn but could still cause reputational or financial harm to the Company.
• Risk of Mr. Dunn raising further allegations or claims, which would trigger indemnification but still require company resources to address.

Future Outlook

The agreement extends the exercise period for Mr. Dunn's vested stock options to 1 year and 9 months post-termination and ensures Directors and Officers Liability Insurance coverage for 6 years from the termination date. The company expects Mr. Dunn to cooperate with any future investigations or proceedings.

Management Comments

• "We enter into this Agreement for ourselves and as agent and trustee for all Group Companies and are authorised to do so."
• "The Company shall procure that the Company's Executive Management Team and Board of Directors shall not make statements about you that are critical, adverse, negative or derogatory, subject at all times to the Company's regulatory and legal obligations."

Industry Context

This filing details a standard executive separation agreement, a common occurrence in the corporate landscape. The terms, including severance, bonus, and extended stock option exercise periods, are typical for high-level executive departures, particularly when aiming for a full release of claims. It does not directly reflect broader industry trends but rather internal corporate governance and human capital management.

Comparison to Industry Standards

• The severance package, including a 12-month notice payment and a discretionary bonus, aligns with common practices for senior executive departures in the pharmaceutical industry, particularly for CFO roles.
• The extension of stock option exercise periods is also a frequent component of such agreements, designed to provide a fair exit while securing a release of claims.
• Specific comparable companies or projects are not mentioned in the filing to allow for a direct comparison of the results of the separation, but the structure of the agreement is standard.

Management Changes

Corporate Governance

Legal Proceedings

• The agreement serves as a full and final settlement of all potential claims by Gordon Dunn against the Company, including claims for breach of contract, wrongful dismissal, and unfair dismissal.
• Mr. Dunn undertakes not to institute any action, claim, or proceedings against the Company or its Group Companies.

Stakeholder Impact

• Shareholders: Incurring costs for severance and bonus, but gaining certainty by resolving potential claims from a former executive. The extension of stock options could dilute future share value if exercised.
• Employees: The departure of a CFO can impact morale or create uncertainty, but the formal resolution provides clarity.
• Management: The CEO, Dr. Michael Myers, signed the agreement, indicating management's direct involvement in resolving the separation.

Next Steps

• Payment of $433,620 in bi-weekly installments to Gordon Dunn.
• Payment of $108,405 bonus to Gordon Dunn on the one-year anniversary of the Termination Date (August 15, 2026).
• Gordon Dunn to return all company property and erase confidential information within 7 days of the agreement date.
• Gordon Dunn to resign from all offices held with the Company and Group Companies.
• Company to procure D&O insurance coverage for Gordon Dunn for 6 years.

Key Dates

Recommendation

The filing details a standard executive separation, which, while involving significant payments, resolves potential liabilities and provides clarity regarding a key management change. It does not present new information that would fundamentally alter the company's operational or financial outlook in a way that warrants a 'buy' or 'sell' recommendation. The costs are quantifiable and likely already factored into market expectations for executive transitions. Therefore, a 'hold' recommendation is appropriate as the news is neutral in its long-term impact.

Keywords

Quoin Pharmaceuticals, Gordon Dunn, CFO departure, settlement agreement, severance package, stock options, corporate governance, executive compensation, QNRX